Carbenicillin Indanyl

Summary

Carbenicillin Indanyl (CHEMBL1596) is an approved small molecule (ATC J01CA05); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA05
• Indications: 2 conditions
• Chemistry: 494.6 Da · C26H26N2O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1596
Name	Carbenicillin Indanyl
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	93184
ChEBI	CHEBI:52015
ATC	J01CA05
Molecular formula	C26H26N2O6S
Molecular weight	494.6
InChIKey	JIRBAUWICKGBFE-MNRDOXJOSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC5=C(CCC5)C=C4)C(=O)O)C

IUPAC name: (2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

Also known as: Carbenicillin indanyl, Carindacilina, Carindacillin, Carindacilline, Indanyl carbenicillin, SID50126360, SID144206652, CARBENICILLIN INDANYL

Parent form; salt/anhydrous children: CHEMBL1200991

Patent coverage: 1,023 distinct patent families (3,923 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,917 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).